News
Moderna's New Lower-Dose COVID-19 Vaccine Approved by FDA
By Stephanie Brown HealthDay ReporterTUESDAY, June 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
A top COVID-19 vaccine advisor has reportedly resigned from her role at the Centers for Disease Control and Prevention in the ...
The resignation follows an order by Health and Human Services Secretary Robert F. Kennedy Jr. to change the agency's guidance ...
The US Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., has recently made significant changes ...
The World Health Organization has tracked a new COVID-19 variant that has emerged across multiple region. Amid this, the Food ...
Health Secretary Robert F. Kennedy Jr. recently announced more key changes to the CDC recommendations for COVID-19 ...
The US Centers for Disease Control and Prevention has updated its immunization schedule for children, days after US Health ...
The St. Lucie News-Tribune on MSN1d
What to know about changes in CDC guidance for COVID-19 vaccineThe CDC says kids 6 months and older with no underlying health conditions can receive the COVID-19 vaccine in consultation ...
Washingtonian on MSN1d
Can Your Child Get the Covid-19 Vaccine? Can You?Vaccination rates across the country have continued to fall since the height of the pandemic, but the coronavirus never ...
Moderna’s newest lower-dose COVID-19 vaccine is approved for all adults 65 and older, and for people aged 12 to 64 who are at ...
A team of US researchers has developed a new type of mRNA vaccine that is more scalable and adaptable to tackle continuously evolving viruses such as SARS-CoV-2 and H5N1.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback